# Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma

> **NCT07731789** · PHASE2 · NOT_YET_RECRUITING · sponsor: **University of Washington** · enrollment: 30 (estimated)

## Conditions studied

- Classic Follicular Lymphoma
- Grade 1 Follicular Lymphoma
- Grade 2 Follicular Lymphoma
- Grade 3a Follicular Lymphoma

## Interventions

- **BIOLOGICAL:** Rituximab
- **BIOLOGICAL:** Tafasitamab
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Aspiration
- **PROCEDURE:** Bone Marrow Biopsy
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Positron Emission Tomography
- **OTHER:** Survey Administration

## Key facts

- **NCT ID:** NCT07731789
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-31
- **Primary completion:** 2030-10-31
- **Final completion:** 2032-10-29
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-09-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07731789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07731789, "Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07731789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*